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Abstract
2-Cyanobenzothiazoles (CBTs) are useful building blocks for: 1) luciferin derivatives for bioluminescent imaging; and 2) handles
for bioorthogonal ligations. A particularly versatile CBT is 6-amino-2-cyanobenzothiazole (ACBT), which has an amine handle for
straight-forward derivatisation. Here we present an economical and scalable synthesis of ACBT based on a cyanation catalysed by
1,4-diazabicyclo[2.2.2]octane (DABCO), and discuss its advantages for scale-up over previously reported routes.
Introduction
Functionalised 2-cyanobenzothiazoles (CBTs, 1) are key build-
ing blocks for the synthesis of luciferins 3 [1-3], substrates of
natural and engineered firefly luciferases that are widely used
for bioluminescence imaging (BLI) [4,5]. The typical prepara-
tion of luciferins 3 involves straightforward condensation of
CBTs 1 with D-cysteine (2) (Scheme 1). For BLI applications,
luciferins are often generated in vivo from CBTs [4-7], which
are easier to modify and handle due to their higher stability, cell
permeability, and reactivity than the full luciferin scaffolds
[2,5,8].
Even in the presence of other thiols and amines, CBTs react
rapidly and selectively with 1,2-aminothiols under physiologi-
cal conditions. This selective and bioorthogonal reactivity of
CBTs has been exploited in the development of the CBT liga-
tion as a useful and fast bioorthogonal reaction (k ≈ 10 M−1s−1)
[9] for site-specific labelling or immobilisation of proteins 4,
either at an N-terminal cysteine residue or at a 1,2-aminothiol
group incorporated into a non-natural amino acid (Scheme 1)
[10,11]. In addition, CBT derivatives have been used for the
synthesis of polymeric nanostructures in cellulo [12,13].
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Scheme 1: Functionalised CBTs 1 can be used for the synthesis of luciferins 3 and for bioorthogonal ligations such as the site-specific labelling/im-
mobilisation of proteins 4.
Scheme 2: Reported synthetic routes to ACBT 8: A) Original route reported by Takakura et al. [14] and Wang et al. [15]. B) The improved route re-
ported by McCutcheon et al. [7].
The precursor of D-aminoluciferin, 6-amino-2-cyanobenzothia-
zole (ACBT, 8), is an attractive building block for BLI probes
and for handles for CBT ligations, because of the ease of
derivatisation of its amino group. Like other functionalised
CBTs, ACBT is available from commercial suppliers, but
expensive. Thus, the development of an economical and scal-
able synthesis of ACBT would enable studies that require larger
amounts of this building block.
The traditional synthesis of ACBT 8 involves the cyanation of
6-amino-2-chlorobenzothiazole (7) with an excess of potassium
cyanide (KCN) in hot DMSO under dilute conditions
(Scheme 2A) [14,15]. However, this reaction is sluggish (partly
because of the poor solubility of KCN in DMSO), requires elab-
orate extractive workups for the removal of DMSO (persistent
traces of which are detrimental to purification) and gives low
and variable yields (typically 30–50% in our hands). In addi-
tion, because DMSO can quickly penetrate the skin, working
with KCN in DMSO requires substantial safety measures.
Therefore, this route does not allow straightforward scale-up
under laboratory conditions. Prescher and co-workers reported
an alternative synthesis of ACBT that avoids the use of cyanide
(Scheme 2B) [7]. This route makes use of 4,5-dichloro-1,2,3-
dithiazolium chloride (Appel’s salt, 12), and variations of the
procedure have enabled the synthesis of different CBT deriva-
tives, some of which on multi-gram scale [6,7,16,17]. However,
Appel’s salt is relatively expensive and available from a limited
number of suppliers, and its synthesis requires the use of the
highly toxic reagent sulfur monochloride [18].
Here, we report an alternative, practical and economical proce-
dure for the preparation of ACBT 8. Our route involves a mild,
organocatalytic cyanation. In addition, the use of filtrations and
crystallisations for purification, in combination with control of
reaction rate and heat output in the cyanation step, makes this
procedure readily scalable.
Results and Discussion
In order to install the cyano group of ACBT 8 under mild condi-
tions, catalytic cyanation procedures were considered. Initial
attempts to use the palladium or copper-catalysed cyanation of
6-amino-2-halobenzothiazoles with potassium hexaferricyanide
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Table 1: DABCO-catalysed cyanation of 6: solvent studies.a
entry solvent(s) conversion of 6b ratio 13:14:15c yield 13d
1 DMSO/H2O 1:1 100% 100:0:0 90%
2 EtOH 100% 17:32:51 ND
3 MeCN/H2O 10:1 100% 100:0:0 75%
aReactions were performed using 200 mg 6 in 20 mL solvent. bConversion of 6 was determined by LC–ESIMS. cIdentities of 13–15 in the reaction
mixtures were confirmed by 1H NMR and LC–MS and product ratios were determined by 1H NMR after work-up. dYields were determined after purifi-
cation; ND = not determined.
– a slow-releasing cyanide source – were unsuccessful. Instead,
a report on the use of 1,4-diazabicyclo[2.2.2]octane (DABCO)
as a catalyst for the cyanation of heteroaryl halides [19] inspired
us to explore the DABCO-catalysed cyanation of 2-chloroben-
zothiazoles.
Indeed, the treatment of 2-chloro-6-nitrobenzothiazole (6) with
DABCO (15 mol %) and sodium cyanide (NaCN, 1.05 equiv) in
DMSO/water 1:1, at room temperature, resulted in full conver-
sion to 2-cyano-6-nitrobenzothiazole (13, Table 1), a known
precursor of ACBT 8 [7]. Any unreacted cyanide in the reac-
tion mixture was safely quenched by the addition of an iron(III)
chloride solution, and pure ACBT 8 was isolated in 90% yield
after (extensive) extractive work-up and flash chromatography.
No conversion of 6 to 13 was observed in the absence of
DABCO, which demonstrates the essential role of DABCO as a
cyanation catalyst under these conditions. In addition, when the
more electron rich 6-amino-2-chlorobenzothiazole (7) was sub-
jected to the DABCO-catalysed cyanation conditions, only
starting material was isolated, even upon heating the reaction
mixture to 100 °C (not shown). This suggests that, although the
cyanation may be adaptable to other 2-halobenzothiazole deriv-
atives, electron-deficient substrates may be required for the
reactions to proceed under mild conditions.
In view of scale-up of the DABCO-catalysed cyanation of 6, an
alternative solvent (mixture) was sought in order to eliminate
safety issues and work-up problems resulting from the use of
DMSO. An initial attempt to run the reaction in water failed
because of the low aqueous solubility of 6 – resulting in a
biphasic reaction mixture – and the slow hydrolysis of 6 under
the reaction conditions according to LC–MS (not shown). The
conversion of 6 was complete in ethanol. However, in addition
to the expected cyano compound 13, significant amounts of side
products 14 (resulting from ethanolysis of 6) and 15 (resulting
from ethanolysis of 13 and subsequent hydrolysis of the inter-
mediate imidate) were formed as well (Table 1, entry 2; Sup-
porting Information File, Figure S7). In contrast, the use of
acetonitrile (with a small volume of water to facilitate dissolu-
tion/addition of NaCN) resulted in full conversion to 13, and
pure 13 which was isolated in 75% yield after quenching with
iron(III) chloride solution, extraction and simple filtration
through a silica plug (Table 1, entry 3). The straightforward
work-up/purification procedure – in the absence of DMSO as a
co-solvent – outweighed the slightly reduced reaction yield on
this scale.
For scale-up of the DABCO-catalysed cyanation, 6 was synthe-
sised by straight-forward nitration of the significantly cheaper
starting material 2-chlorobenzothiazole (16) [15], and isolated
in 82% yield after crystallisation from ethanol (Scheme 3).
Recrystallisation of 16 from acetonitrile required only 25% of
the solvent volume, but resulted in a slightly lower yield (73%).
In view of potential dangers involved in the use of NaCN on
large scale, a calorimetric analysis was conducted to monitor
the heat output of the cyanation reaction. In this experiment,
aqueous NaCN (49 mg in 2 mL) was slowly added to a solution
of 6 (200 mg) and DABCO (15 mol %) in acetonitrile (20 mL;
compound 6 dissolves in acetonitrile only upon addition of
DABCO). The calorimeter jacket temperature was set at 1 °C,
and power compensation by an internal heater coil was used to
maintain the reactor temperature at 21 °C. The reaction resulted
in an endotherm (Figure 1A). The total power released or con-
sumed by the reaction (QTotal) was calculated by subtracting
the power generated due to the temperature and specific heat
capacity of the feed (QDose) from the compensatory power
supplied by the internal heater coil (QComp). Because QDose
remained at zero throughout the reaction, the traces for QComp
and QTotal overlap in Figure 1A. From QTotal, an energy
consumption of 0.42 kJ was determined for the addition of
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Figure 1: Calorimeter traces for the addition of aqueous NaCN (A) or water (B) to a solution of 6 and DABCO in acetonitrile. QComp: compensatory
power; QTotal: total power; QDose: power generated due to the temperature and heat capacity of the feed; energy: heat energy. Because QDose ≈ 0
over the course of the experiment, traces for QComp (orange) and QTotal (blue) overlap.
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Scheme 3: Scale-up of ACBT synthesis.
1 mmol of NaCN in 2 mL of water. A control experiment, in
which only water was added to 6 and DABCO in acetonitrile,
showed an endotherm of 0.51 kJ, corresponding to a calculated
heat of mixing of water into the reaction mixture of
ΔH = 4.57 kJ mol−1 (see Supporting Information File 1). These
observations complicated accurate quantification of the heat of
reaction (because of different properties of the feeds in the two
experiments). The difference in endotherms between the cyana-
tion reaction (Figure 1A) and the control experiment
(Figure 1B) suggests the overall DABCO-catalysed reaction of
6 and NaCN is exothermic, but that the endothermic addition of
water to the acetonitrile solution outweighs this exotherm under
the experimental conditions. Our results suggest that a slow ad-
dition of a dilute aqueous NaCN solution is a safe method for
scale-up of the cyanation reaction, provided the concentration
of the solution allows an overall reaction endotherm to be main-
tained to prevent potential thermal runaway upon scale-up.
The DABCO-catalysed cyanation reaction was scaled up in two
steps: using 2 g and then 10 g of substrate 6 (Scheme 3). After
quenching with iron(III) chloride solution, extractive work-up
and filtration through a short silica plug, product 13 was isolat-
ed in 83–93% yield. A sample of 13 for melting point determi-
nation was obtained by recrystallisation from methanol. The
synthesis of ACBT 8 was completed by reduction of the nitro
group in 13 (Scheme 3). In our hands, the use of iron powder in
acetic acid proved more practical than the previously reported
procedures with zinc powder and ammonium chloride [7]. It
resulted in more consistent yields, an easier work-up, and no
persistent contamination of 8 with nitroso intermediates [6].
The reduction step was accomplished on a 1 g and 5 g scale
isolating ACBT 8 by filtration through a short silica plug to
give the desired product in 60–71% yield. Pure product 8 was
recrystallised from hot ethanol for melting point determination.
Conclusion
We have developed a straight-forward, practical and readily
scalable synthesis of ACBT 8, a valuable intermediate in the de-
velopment of chemical probes for bioorthogonal ligation and
bioluminescent imaging. The procedure allowed the safe syn-
thesis of 8 at multigram scale and in high purity. In addition, the
sole use of filtrations and crystallisations for purification of all
intermediates and products, in combination with the
endothermic nature of the controlled cyanation procedure, will
enable straightforward further scale up, if required. A direct
comparison of our route to ACBT 8 to those published by
others is shown in the Supporting Information File 1, clearly
revealing our route as the most suitable for scale-up.
Experimental
General experimental
All chemical reagents were purchased from commercial
suppliers and used without further purification. The identity and
purity of known compounds was confirmed through the com-
parison of experimentally obtained data to values reported in
the literature. 1H and 13C NMR spectra were recorded in deuter-
ated solvents on a Bruker Avance 500 spectrometer. Chemical
shifts are referenced to residual solvent peaks and are quoted in
ppm. Coupling constants (J) are reported to the nearest 0.1 Hz.
Assignment of spectra was based on expected chemical shifts
and coupling constants, aided by COSY, HMQC, and HMBC,
where appropriate. Calorimetry experiments were carried out
using HEL AutoMATE parallel reactors with HEL WinISO
2225 and HEL IQ 1.2.16 software. Temperature was controlled
using a Julabo refrigerated/heating circulator (Model FP50-HD)
and feed reactants introduced into the reaction using a Harvard
syringe pump (model pump 11) connected to a 20 mL dispos-
able syringe with an 8 inch, 16 gauge Luer fitting syringe
needle.
Reaction procedures
2-Chloro-6-nitro-1,3-benzothiazole (6) [15,20]
2-Chloro-1,3-benzothiazole (16, 10.0 g, 58.95 mmol) was added
portion wise to concentrated H2SO4 (60 mL) in a cooled round-
bottomed flask (ice bath). Potassium nitrate (6.56 g,
64.85 mmol) was added portion wise, and the resulting reaction
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mixture was stirred at 0 °C (ice bath) for 30 min, and then at
room temperature for 18 h. The solution was poured onto ice
and the formed precipitate collected by filtration. The collected
solid was rinsed with ice cold water until acid free, and then
dried under reduced pressure. The crude product was further
purified by recrystallisation from MeCN (≈ 100 mL) or EtOH
(≈ 425 mL) to yield 6 as fine off-white needles. Yield from
EtOH (10.37 g, 48.34 mmol, 82%), from MeCN (9.21 g, 42.89
mmol, 73%). Mp 193–194 °C (EtOH); 1H NMR (500 MHz,
CDCl3) δ 8.75 (d, J = 2.3 Hz, 1H, CH-7), 8.38 (dd, J = 9.0, 2.3
Hz, 1H, CH-5), 8.07 (d, J = 9.0 Hz, 1H, CH-4); 13C NMR (125
MHz, CDCl3) δ 158.9 (C-2), 154.9 (C-6), 145.6 (C-7a), 136.6
(C-3a), 123.5 (CH-4), 122.4 (CH-5), 117.8 (CH-7).
6-Nitro-1,3-benzothiazole-2-carbonitrile (13) [19]
A solution of NaCN (2.40 g, 48.97 mmol) in H2O (100 mL)
was added slowly to a stirred solution of 2-chloro-6-nitro-1,3-
benzothiazole (6, 10.0 g, 46.59 mmol) and DABCO (748 mg,
6.99 mmol) in MeCN (1000 mL). The reaction mixture was
stirred at room temperature for 24 h. Excess cyanide was
quenched by the addition of an aqueous FeCl3 solution (0.3 M,
30 mL). The reaction mixture was diluted with H2O (470 mL)
and extracted with EtOAc (3 × 400 mL). The organic layers
were combined, washed with brine (100 mL), dried with
Na2SO4, filtered, and concentrated in vacuo to give a yellow
solid. The crude product was loaded onto a short plug of silica
gel, flushed through with CHCl3 (ca. 1 L) and concentrated in
vacuo to give 13 as a white solid (7.89 g, 38.44 mmol, 83%). A
sample of 13 was crystallised from MeOH for melting point
analysis. Rf 0.37 (SiO2, CHCl3); mp 164–165 °C (MeOH); 1H
NMR (500 MHz, CDCl3) δ 8.96 (d, J = 2.1 Hz, 1H, CH-7), 8.52
(dd, J = 9.1, 2.1 Hz, 1H, CH-5), 8.38 (d, J = 9.1 Hz, 1H, CH-4);
13C NMR (125 MHz, CDCl3) δ 155.5 (C-6), 147.4 (C-7a),
141.9 (C-2), 135.7 (C-3a), 126.2 (CH-4), 123.2 (CH-5), 118.7
(CH-7), 112.1 (C≡N).
6-Amino-1,3-benzothiazole-2-carbonitrile (8) [21]
Iron powder (68.05 g, 1218.55 mmol) was added to a suspen-
sion of 6-nitro-1,3-benzothiazole-2-carbonitrile (13, 5.00 g,
24.37 mmol) in acetic acid (500 mL). The reaction mixture was
stirred at room temperature for 24 h, diluted with water (1 L)
and unreacted iron was removed by filtration through celite.
The aqueous solution was extracted with EtOAc (4 × 500 mL).
The combined organic layers were washed with brine (2 ×
300 mL), dried (Na2SO4) and concentrated in vacuo. The crude
product was loaded onto a short plug of silica gel, flushed
through with CHCl3 (ca. 1 L) and concentrated in vacuo to give
8 as yellow microcrystals (3.02 g, 17.24 mmol, 71%). A sam-
ple of 13 was crystallised from EtOH for melting point analysis.
Rf 0.2 (SiO2, DCM); mp 219–220 °C (EtOH); 1H NMR
(500 MHz, CDCl3) δ 7.95 (d, J = 8.9 Hz, 1H, CH-4), 7.08 (d, J
= 2.2 Hz, 1H, CH-7), 6.95 (dd, J = 8.8, 2.2 Hz, 1H, CH-5), 4.14
(s, 2H, NH2); 13C NMR (125 MHz, CDCl3) δ 147.8 (C-6),
145.7 (C-7a), 138.3 (C-3a), 131.2(C-2), 126.1 (CH-4), 117.8
(CH-5), 113.7 (C≡N), 104.0 (CH-7).
Supporting Information
Supporting Information File 1
Copies of 1H and 13C NMR spectra, details of calorimetry
experiments and comparison of routes to ACBT 8.
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Acknowledgements
We thank EPSRC for funding (DTA studentship to HAB), Prof.
John Blacker for help with interpretation of calorimetry results
and Dr Martin Fisher and Dr James Murray for initial ACBT
scale up studies.
References
1. White, E. H.; McCapra, F.; Field, G. F. J. Am. Chem. Soc. 1963, 85,
337–343. doi:10.1021/ja00886a019
2. White, E.; Wörther, H. J. Am. Chem. Soc. 1966, 88, 2015–2019.
doi:10.1021/ja00961a030
3. Meroni, G.; Rajabi, M.; Santaniello, E. ARKIVOC 2009, 2009, 265–288.
doi:10.3998/ark.5550190.0010.109
4. Godinat, A.; Budin, G.; Morales, A. R.; Park, H. M.; Sanman, L. E.;
Bogyo, M.; Yu, A.; Stahl, A.; Dubikovskaya, E. A. A Biocompatible
“Split Luciferin” Reaction and Its Application for Non-Invasive
Bioluminescent Imaging of Protease Activity in Living Animals. Current
Protocols in Chemical Biology; Wiley, 2014; Vol. 6, pp 169–189.
doi:10.1002/9780470559277.ch140047
5. Godinat, A.; Park, H. M.; Miller, S. C.; Cheng, K.; Hanahan, D.;
Sanman, L. E.; Bogyo, M.; Yu, A.; Nikitin, G. F.; Stahl, A.;
Dubikovskaya, E. A. ACS Chem. Biol. 2013, 8, 987–999.
doi:10.1021/cb3007314
6. Porterfield, W. B.; Jones, K.; McCutcheon, D. C.; Prescher, J.
J. Am. Chem. Soc. 2015, 137, 8656–8659. doi:10.1021/jacs.5b02774
7. McCutcheon, D. C.; Porterfield, W. B.; Prescher, J. Org. Biomol. Chem.
2015, 13, 2117–2121. doi:10.1039/C4OB02529F
8. White, E. H.; Steinmetz, M. G.; Miano, J. D.; Wildes, P. D.; Morland, R.
J. Am. Chem. Soc. 1980, 102, 3199–3208. doi:10.1021/ja00529a051
Beilstein J. Org. Chem. 2016, 12, 2019–2025.
2025
9. Lang, K.; Chin, J. W. ACS Chem. Biol. 2014, 9, 16–20.
doi:10.1021/cb4009292
10. Ren, H.; Xiao, F.; Zhan, K.; Kim, Y.-P.; Xie, H.; Xia, Z.; Rao, J.
Angew. Chem., Int. Ed. 2009, 48, 9658–9662.
doi:10.1002/anie.200903627
11. Nguyen, D. P.; Elliott, T.; Holt, M.; Muir, T. W.; Chin, J. W.
J. Am. Chem. Soc. 2011, 133, 11418–11421. doi:10.1021/ja203111c
12. Liang, G.; Ren, H.; Rao, J. Nat. Chem. 2010, 2, 54–60.
doi:10.1038/nchem.480
13. Ye, D.; Pandit, P.; Kempen, P.; Lin, J.; Xiong, L.; Sinclair, R.; Rutt, B.;
Rao, J. Bioconjugate Chem. 2014, 25, 1526–1536.
doi:10.1021/bc500254g
14. Takakura, H.; Kojima, R.; Urano, Y.; Terai, T.; Hanaoka, K.; Nagano, T.
Chem. – Asian J. 2011, 6, 1800–1810. doi:10.1002/asia.201000873
15. Wang, P.; Zhang, C.-J.; Chen, G.; Na, Z.; Yao, S. Q.; Sun, H.
Chem. Commun. 2013, 49, 8644–8646. doi:10.1039/c3cc43566k
16. McCutcheon, D. C.; Paley, M. A.; Steinhardt, R. C.; Prescher, J. A.
J. Am. Chem. Soc. 2012, 134, 7607. doi:10.1021/ja301493d
17. Steinhardt, R. C.; O’Neill, J. M.; Rathbun, C. M.; McCutcheon, D. C.;
Paley, M. A.; Prescher, J. A. Chem. – Eur. J. 2016, 22, 3671–3675.
doi:10.1002/chem.201503944
18. The National Institute for Occupational Safety and Health (NIOSH):
‘sulfur monochloride‘, December 4, 2014.
http://www.cdc.gov/niosh/idlh/10025679.html (accessed May 27, 2016).
19. Sviridov, S.; Kodumuru, V.; Liu, S.; Abreo, M.; Winther, M. D.;
Gschwend, H. W.; Kamboj, R.; Sun, S.; Holladay, M. W.; Li, W.; Tu, C.
Piperazine derivatives and their use as therapeutic agents. WO
2005011657 A2, Feb 10, 2005.
20. Katz, L. J. Am. Chem. Soc. 1951, 73, 4007–4010.
doi:10.1021/ja01152a132
21. Brinkman, J. A.; Donnell, A. F.; Kester, R. F.; Qian, Y.; Sarabu, R.;
So, S. Antiviral compounds. WO 2012175581 A1, Dec 27, 2012.
License and Terms
This is an Open Access article under the terms of the
Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of Organic
Chemistry terms and conditions:
(http://www.beilstein-journals.org/bjoc)
The definitive version of this article is the electronic one
which can be found at:
doi:10.3762/bjoc.12.189
